Literature DB >> 14984024

Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis.

Lionel B Ivashkiv1.   

Abstract

Type I interferons (IFNs) are pleiotropic cytokines that have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). A key aspect of type I IFN biology is that previous exposure to type I IFNs alters subsequent cellular responses to extracellular stimuli. Type I IFNs may either prime cells for stronger responses to viruses, bacterial pathogens and cytokines such as IL-6 and IFN-gamma, or may suppress cellular responses to LPS and TNFalpha. Herein, we review type I IFN signal transduction via the Jak-STAT pathway, and mechanisms by which type I IFNs prime or suppress responses to environmental factors. We develop a hypothesis that type I IFN-dependent priming/enhancement of cellular responses to pro-inflammatory cytokines such as IFNgamma and IL-6 contributes to pathogenesis of SLE. In addition, cross-regulation between type I IFNs and TNFalpha and its potential role in SLE pathogenesis is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14984024     DOI: 10.1080/08916930310001605882

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  30 in total

1.  Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes.

Authors:  Ramon Gimeno; Chien-Kuo Lee; Christian Schindler; David E Levy
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

2.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

3.  A novel type II membrane receptor up-regulated by IFN-alpha in fibroblasts functions in cell proliferation through the JAK-STAT signalling pathway.

Authors:  L-D Liu; C-H Dong; H-J Shi; H-L Zhao; L-C Wang; S-H Ma; Q-H Li
Journal:  Cell Prolif       Date:  2006-04       Impact factor: 6.831

4.  Positive correlation of STAT1 and miR-146a with anemia in patients with systemic lupus erythematosus.

Authors:  Paul R Dominguez-Gutierrez; Angela Ceribelli; Minoru Satoh; Eric S Sobel; Westley H Reeves; Edward K L Chan
Journal:  J Clin Immunol       Date:  2013-12-01       Impact factor: 8.317

5.  Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells.

Authors:  Tae Whan Kim; Seunghee Hong; Yin Lin; Elise Murat; HyeMee Joo; Taeil Kim; Virginia Pascual; Yong-Jun Liu
Journal:  J Immunol       Date:  2016-09-14       Impact factor: 5.422

Review 6.  Absent in Melanoma 2 proteins in SLE.

Authors:  Divaker Choubey; Ravichandran Panchanathan
Journal:  Clin Immunol       Date:  2017-01-03       Impact factor: 3.969

7.  Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis.

Authors:  Li Li; Lori J Silveira; Nabeel Hamzeh; May Gillespie; Peggy M Mroz; Annyce S Mayer; Tasha E Fingerlin; Lisa A Maier
Journal:  Eur Respir J       Date:  2016-04-21       Impact factor: 16.671

8.  Role of Leptin and SOCS3 in Inhibiting the Type I Interferon Response During Obesity.

Authors:  Elí Terán-Cabanillas; Jesús Hernández
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 9.  Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.

Authors:  Tineke Cantaert; Dominique Baeten; Paul P Tak; Lisa G M van Baarsen
Journal:  Arthritis Res Ther       Date:  2010-10-28       Impact factor: 5.156

10.  Modulation of TNF-induced macrophage polarization by synovial fibroblasts.

Authors:  Laura T Donlin; Arundathi Jayatilleke; Eugenia G Giannopoulou; George D Kalliolias; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2014-07-23       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.